A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype
2016 · Oncogene · 56 citations
https://doi.org/10.1038/onc.2016.134
R
Raju Kandimalla
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
190
Papers
2.0K
Citations
25
h-index
31
i10-index
Raju Kandimalla is an academic researcher from Bristol-Myers Squibb (Germany). The author has contributed to research in topics: Epigenetics and DNA Methylation & Bladder and Urothelial Cancer Treatments & Cancer-related molecular mechanisms research. The author has an h-index of 25, co-authored 162 publications.
ORCID: 0000-0002-0342-5229Papers by this author
worksSafety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer
2024 · Annals of Oncology · 55 citations
https://doi.org/10.1016/j.annonc.2024.09.005
Relationship between genome and epigenome - challenges and requirements for future research
2014 · BMC Genomics · 33 citations
https://doi.org/10.1186/1471-2164-15-487
RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level
2019 · npj Precision Oncology · 25 citations
https://doi.org/10.1038/s41698-019-0085-2
Modeling Personalized Adjuvant TreaTment in EaRly stage coloN cancer (PATTERN)
2020 · The European Journal of Health Economics · 9 citations
https://doi.org/10.1007/s10198-020-01199-4
1597MO Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
2024 · Annals of Oncology · 3 citations
https://doi.org/10.1016/j.annonc.2024.08.1678
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat